Technology & Software Global On demand · 24-48h

Global GPCR Screening Service Market Strategic Research Report

Global GPCR Screening Service Market Strategic Research Repo…
$3,500 USD
Market Research Reports
Strategic Research Report
Global GPCR Screening Service Market
$3772025
7.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Gs Pathway Screening, Gi/o Pathway Screening, Gq Pathway Screening, G12/13 Pathway Screening

By Application: Pharmaceuticals, Disease Treatment, Research, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Eurofins Discovery, Charles River Laboratories International, Inc., Reaction Biology Corporation, Sygnature Discovery Limited, Evotec SE, Multispan, Inc., Pharmaron Beijing Co., Ltd., PharmaLegacy Laboratories, BioAscent Discovery Limited, Creative Biogene, Creative Bioarray, ICE Bioscience, Shanghai Jinsirui Vigorous Biotechnology Co., Ltd., Promega Corporation, Proteros biostructures GmbH, Aragen Life Sciences, BPS Bioscience, Inc., Revvity, Inc., Genscript Biotech Corporation, Beijing Abace Biotechnology Co., Ltd., MedChemExpress LLC, BrainVTA (Wuhan) Co., Ltd., Genevoyager Biopharmaceutical Technology (Wuhan) Co., Ltd., Penn State GPCR Assay Service Center, Celtarys Research

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 147 pages
Market size 2025
$377
Million USD
Forecast CAGR
7.4%
2025-2032
Forecast 2032
$621.4
Projected
Regionen
5
Asia Pacific · Latin America · MEA · Europe · North America

Übersicht

Scope of the Report

The global GPCR Screening Service market size is predicted to grow from US$ 377 million in 2025 to US$ 621 million in 2032; it is expected to grow at a CAGR of 7.4% from 2026 to 2032.

GPCR screening services are professional in vitro pharmacological testing services for drug discovery and early-stage research and development. Focusing on G protein-coupled receptor targets, these services help clients discover, confirm, and optimize candidate molecules acting on GPCR targets through cell line construction, receptor expression verification, binding experiments, functional experiments, signal pathway detection, initial compound screening, dose-response confirmation, selectivity evaluation, off-target safety spectral screening, and biased signal analysis.

From a demand structure perspective, targets related to metabolic diseases, obesity, diabetes, neurological diseases, pain, cardiovascular diseases, immune inflammation, and the tumor microenvironment are significant sources of demand for GPCR screening services. The continued development of GLP-1R, GIPR, GCGR, 5-HT receptors, opioid receptors, chemokine receptors, adenosine receptors, S1P receptors, cannabinoid receptors, and orphan GPCRs is driving pharmaceutical and biotechnology companies to conduct receptor function screening, selective profiling, and off-target safety evaluation. With advancements in structural biology, cryo-electron microscopy, AI-assisted molecular design, and allosteric modulator development, customer demand for GPCR services is shifting from "single activity screening" to a combination of services encompassing "multiple pathways, multiple readings, multiple species, and mechanism interpretation." Service providers with orthogonal assay design capabilities are more likely to secure high-value projects.

This report presents a comprehensive overview of the global GPCR Screening Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Gs Pathway Screening
  • Gi/o Pathway Screening
  • Gq Pathway Screening
  • G12/13 Pathway Screening

Segment by Detection Technology

  • cAMP Detection
  • Calcium Flow Detection
  • IP1 Detection

Segment by Number of Compounds Screened Per Session

  • <1,000
  • 1,000~10,000
  • 10,000~100,000
  • >100,000

Segment by Application

  • Pharmaceuticals
  • Disease Treatment
  • Research
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global GPCR Screening Service market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Pharmaceuticals, Disease Treatment, Research evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global GPCR Screening Service Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 7.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$377
2025
Forecast
$621.4
2032
CAGR
7.4%
2025–2032
Regionen
5
global
Key companies
Eurofins DiscoveryCharles River Laboratories International, Inc.Reaction Biology CorporationSygnature Discovery LimitedEvotec SEMultispan, Inc.Pharmaron Beijing Co., Ltd.PharmaLegacy Laboratories
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Gs Pathway ScreeningGi/o Pathway ScreeningGq Pathway ScreeningG12/13 Pathway Screening
By Application
PharmaceuticalsDisease TreatmentResearchOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Gs Pathway Screening
  • 3.1.3 Gi/o Pathway Screening
  • 3.1.4 Gq Pathway Screening
  • 3.1.5 G12/13 Pathway Screening
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Pharmaceuticals
  • 4.1.3 Disease Treatment
  • 4.1.4 Research
  • 4.1.5 Other
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Eurofins Discovery
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Charles River Laboratories International, Inc.
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Reaction Biology Corporation
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Sygnature Discovery Limited
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Evotec SE
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Multispan, Inc.
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Pharmaron Beijing Co., Ltd.
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 PharmaLegacy Laboratories
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 BioAscent Discovery Limited
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Creative Biogene
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Creative Bioarray
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 ICE Bioscience
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Shanghai Jinsirui Vigorous Biotechnology Co., Ltd.
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Promega Corporation
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Proteros biostructures GmbH
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Aragen Life Sciences
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 BPS Bioscience, Inc.
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Revvity, Inc.
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Genscript Biotech Corporation
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Beijing Abace Biotechnology Co., Ltd.
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 MedChemExpress LLC
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 BrainVTA (Wuhan) Co., Ltd.
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Genevoyager Biopharmaceutical Technology (Wuhan) Co., Ltd.
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 Penn State GPCR Assay Service Center
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 Celtarys Research
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global GPCR Screening Service market?
The global GPCR Screening Service market is estimated at US$ 377 million in 2025 (base year) and is projected to reach US$ 621 million by 2032.
How fast is the GPCR Screening Service market expected to grow?
The market is expected to grow at a CAGR of 7.4% from 2026 to 2032, expanding from US$ 377 million in 2025 to US$ 621 million in 2032, roughly 1.6 times its base-year value.
What does the GPCR Screening Service market cover?
GPCR screening services are professional in vitro pharmacological testing services for drug discovery and early-stage research and development.
What are the main segments of the GPCR Screening Service market by type?
By type, the market is segmented into Gs Pathway Screening, Gi/o Pathway Screening, Gq Pathway Screening and G12/13 Pathway Screening.
Which applications drive demand in the GPCR Screening Service market?
Key applications covered include Pharmaceuticals, Disease Treatment, Research and Other.
Who are the key players in the GPCR Screening Service market?
Key players profiled include Eurofins Discovery, Charles River Laboratories International, Reaction Biology Corporation, Sygnature Discovery Limited, Evotec SE, Multispan, Pharmaron Beijing Co. and PharmaLegacy Laboratories, among 25 companies covered in total.
Which regions and countries are covered for GPCR Screening Service?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the GPCR Screening Service market?
The continued development of GLP-1R, GIPR, GCGR, 5-HT receptors, opioid receptors, chemokine receptors, adenosine receptors, S1P receptors, cannabinoid receptors, and orphan GPCRs is driving pharmaceutical and biotechnology companies to conduct receptor function screening, selective profiling, and off-target safety evaluation.
Who should buy the GPCR Screening Service market report?
The report is intended for manufacturers and solution providers, distributors and end users in Pharmaceuticals, Disease Treatment and Research, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the GPCR Screening Service market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3.500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.